GSK

We believe every breath matters. This #ATS2025 we shared research that adds to decades of evidence shaping the landscape of respiratory medicine. While patients with asthma and COPD continue to need emergency hospital care, we will apply our expertise in respiratory medicines to go beyond symptom relief to protect people from exacerbations, lung damage and disease progression. Now is the time to apply the evidence so that patients can start to benefit 👇 https://gsk.to/3SfCaAZ

We’re reflecting on the past few days at #ATS2025, motivated by what we’ve achieved and inspired to continue our work to redefine respiratory care. Hear more from Kaivan Khavandi, Senior Vice President and Global Head of Respiratory, Immunology & Inflammation, as he shares his insights and key takeaways from an exciting few days in San Francisco.

This week at the biannual International Congress on Systemic Lupus Erythematosus, we’re proud to share research that reinforces the importance of early intervention for people living with lupus. Early intervention can change the trajectory of this chronic autoimmune disease for patients with systemic lupus erythematosus (SLE). Without it, people living with lupus can experience more severe disease flares, faster disease progression and long-lasting organ damage. Prioritize talking with people living with lupus, earlier, for more effective disease management. #LUPUS2025

On #WorldDayforCulturalDiversity, we’re celebrating inclusion as a powerful part of our culture, helping us make better decisions and discover innovative solutions. And because diseases and medicines can affect people differently depending on their ethnicity, sex, race and age, we’re working to ensure our clinical trials include those affected by the disease under study. This helps us generate better data and develop medicines and vaccines that meet real patient needs.   Today we’re sharing Michel Reid’s story, and how his experience contributes to improving representation in our clinical trials.    Find out more about our approach to clinical trials: https://lnkd.in/dbZBNTFU    #WDCDDD

Congratulations to Tony Wood, our Chief Scientific Officer, who today has been elected a Fellow of The Royal Society. This honour recognises his significant contribution to science and use of technology to discover and develop much needed medicines and vaccines, and reflects his ion and commitment to the patients he serves. Tony’s work has touched the health of many and will leave a lasting mark on the field, offering inspiration for generations of scientists to come. Science and tech are at the heart of what we do at GSK, and we’re so proud to have Tony leading our talented scientists to get ahead of disease, together. 🔗 Discover more about Tony’s scientific background: https://gsk.to/44MkmF8

Steve, a GSK employee, who has asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), found his symptoms were getting worse. Steve was experiencing frequent exacerbations, waking unable to breathe. “At my lowest eeb with asthma, when it was really at its worst, I was taking additional medication in the form of oral-corticosteroids, probably 5 or 6 courses a year. And that really concerned me because I was aware of the dangers of taking regular doses of oral corticosteroids.” Concerned not only about his symptoms, but also the potential harm associated with oral cortico-steroids. He knew he had to do something and seek help. We’re proud to be at #ATS2025 to highlight how we can move beyond symptom control and target the underlying disease to deliver meaningful treatment solutions and help millions more people like Steve. Watch Steve’s story and learn more https://gsk.to/437eYLz

#News for #Investors and #Media The Japan Ministry of Health, Labour and Welfare (MHLW) has approved one of our blood cancer therapies. Find more information here: https://gsk.to/4k6hoA0

We’re at #ATS2025 and excited to share our latest research from across 40 abstracts from our portfolio of inhaled therapies, biologics and pipeline assets. Here Court Horncastle, SVP, US Specialty Business Unit head, shares his thoughts on what he feels are the key data and why #ATS2025 is so important to getting ahead of respiratory disease. https://gsk.to/45fqqpG

Collaboration is key to addressing some of the biggest challenges in respiratory health and getting ahead of respiratory conditions like chronic obstructive pulmonary disease (COPD). This is why we are of the Speak Up for COPD initiative. At #ATS2025 we will meet with global experts, patient advocates and patients so that we can learn, share ideas and find new ways to achieve ambitious treatment goals for people with respiratory diseases.

We believe getting ahead of respiratory disease demands breathtaking innovation. At this year's #ATS2025 we are sharing data from over 40 abstracts, including 4 late-breaker submissions. This data line-up is testament to our long-term focus to improve outcomes for a wide range of patients suffering from complex respiratory diseases. Our expertise is helping us to get ahead of symptoms, exacerbations, and disease progression so that people with respiratory diseases can live healthier lives. Learn more👇 https://gsk.to/4jYurU8